Announcements Trials

Browse Landscape

Phase

Phase 2 23 Phase 1 23 Phase NA 16 Phase 3 12 Phase 1/2 11 Phase EARLY_PHASE1 1 Phase 2/3 1

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 10 Other hematologic neoplasm 5 CNS 4 Head & Neck 3 Genitourinary 3 Gastrointestinal 3 Thoracic 2 Myeloid 1 Breast 1

Conditions

Breast Neoplasms 117 Triple Negative Breast Neoplasms 9 Neoplasms 4 Neoplasm Metastasis 4 Lung Neoplasms 4 HER2-positive Breast Cancer 4 Prostatic Neoplasms 3 Motor Activity 3 Melanoma 3 Inflammatory Breast Neoplasms 3 Head and Neck Neoplasms 3 Depression 3 Colorectal Neoplasms 3 Sarcoma 2 Peripheral Nervous System Diseases 2 Ovarian Neoplasms 2 Fatigue 2 Carcinoma, Ductal, Breast 2 Breast Diseases 2 Breast Carcinoma In Situ 2 Anxiety Disorders 2 Uterine Cervical Neoplasms 1 Urogenital Neoplasms 1 Urinary Incontinence 1 To Evaluate the Effectiveness of GM1 in the Prevention of Albumin-paclitaxel Therapy Induced Peripheral Neuropathy in Breast Cancer Patients 1 Smoking 1 Sleepiness 1 Seroma 1 Recurrence 1 Radiodermatitis 1

Interventions

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2/3 × Recurrence × Breast × Clear all

NCT03315364 2026-04-01

OPTIMAL

Daehwa Pharmaceutical Co., Ltd.

Phase 2/3 Active not recruiting

Breast Neoplasms, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon ⚡